The Molecular Pathology Shared Resource (MPSR) represents amalgamation of three existing cores (Cytogenetics, DNA Sequencing, and Pre-analytical Evaluation and Molecular Testing) into a thematically related and operationally coordinated unit. This consolidation creates a seamlessly integrated Shared Resource that mirrors an established CLIA-certified clinical service unit in the Department of Pathology. MPSR will facilitate the development and validation of clinical assays for diagnosis, prognostication, and, most importantly, prediction of response to molecular therapeutic agents for UCCC members. The newly organized Cytogenetics, DNA Sequencing, and Pathology Cores all have a long history within the UCCC. The Cytogenetics Core was started in 1988 and, since 1996, has been under the direction of Dr. Varella-Garcia. The Core began by providing UCCC members access to classical cytogenetic technology and has evolved over the years, in response to the scientific progress in the field, to provide members access to advanced technologies in both classical and molecular cytogenetics. The DNA Sequencing &Analysis Core has enjoyed a similar history, reputation and success. Dr. Korch has been with the (Dore since 1996, first as the manager, and more recently as the Director. The DNA Service is now the major in-state provider of DNA sequencing services to researchers in Colorado, performing basic, translational, and clinical cancer research, including CLIA-certified DNA sequencing services. The Pathology Core was established by Dr. Franklin's predecessor, Dr Gary Miller, in 1986 as one of the founding cores of the UCCC. Over the past 24 years, the core has provided tissue banking and histological services in support of UCCC research activities. Five years ago, lasercapture microdissection services were added to the resource. In 2008, the institution was awarded a clinical and translational sciences award (Colorado Clinical and Translational Sciences Initiative, or CCTSI), under which coordinated biobanking became a priority. Cancer Center leadership used this opportunity to leverage institutional and CCTSI support by consolidating tissue repository services previously under the Pathology Service Core, under the new leadership of Dr. Scott Lucia. This created a new UCCC Tissue Biobanking and Processing Shared Resource (TBP) Shared Resource.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-26
Application #
8616658
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
26
Fiscal Year
2014
Total Cost
$3,231
Indirect Cost
$2,876
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Ren, Shengxiang; Rivard, Christopher J; Yu, Hui et al. (2018) A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clin Lung Cancer 19:450-456
Donson, Andrew M; Amani, Vladimir; Warner, Elliot A et al. (2018) Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol Cancer Ther 17:1984-1994
Branchford, B R; Stalker, T J; Law, L et al. (2018) The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost 16:352-363
Pei, Shanshan; Minhajuddin, Mohammad; Adane, Biniam et al. (2018) AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell 23:86-100.e6
Ryan, Weston Kenneth; Fernandez, Josiah; Peterson, Mikayla Katherine et al. (2018) Activation of S6 signaling is associated with cell survival and multinucleation in hyperplastic skin after epidermal loss of AURORA-A Kinase. Cell Death Differ :
Monks, Jenifer; Orlicky, David J; Stefanski, Adrianne L et al. (2018) Maternal obesity during lactation may protect offspring from high fat diet-induced metabolic dysfunction. Nutr Diabetes 8:18
Garcia, Tamara B; Fosmire, Susan P; Porter, Christopher C (2018) Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine. Leuk Res 64:30-33
Wahdan-Alaswad, R S; Edgerton, S M; Salem, H S et al. (2018) Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer. J Oncol Transl Res 4:
Oweida, Ayman; Phan, Andy; Vancourt, Benjamin et al. (2018) Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. Thyroid 28:739-747
Gadalla, Shahinaz M; Wang, Tao; Loftus, David et al. (2018) No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia. Bone Marrow Transplant 53:383-391

Showing the most recent 10 out of 1634 publications